1. Home
  2. ONCO vs APVO Comparison

ONCO vs APVO Comparison

Compare ONCO & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ONCO
  • APVO
  • Stock Information
  • Founded
  • ONCO 2018
  • APVO 2016
  • Country
  • ONCO United States
  • APVO United States
  • Employees
  • ONCO N/A
  • APVO N/A
  • Industry
  • ONCO Biotechnology: Pharmaceutical Preparations
  • APVO Biotechnology: Pharmaceutical Preparations
  • Sector
  • ONCO Health Care
  • APVO Health Care
  • Exchange
  • ONCO Nasdaq
  • APVO Nasdaq
  • Market Cap
  • ONCO 9.4M
  • APVO 6.5M
  • IPO Year
  • ONCO 2022
  • APVO N/A
  • Fundamental
  • Price
  • ONCO $0.60
  • APVO $3.95
  • Analyst Decision
  • ONCO
  • APVO Strong Buy
  • Analyst Count
  • ONCO 0
  • APVO 1
  • Target Price
  • ONCO N/A
  • APVO $296.00
  • AVG Volume (30 Days)
  • ONCO 10.4M
  • APVO 46.8K
  • Earning Date
  • ONCO 12-10-2024
  • APVO 03-04-2025
  • Dividend Yield
  • ONCO N/A
  • APVO N/A
  • EPS Growth
  • ONCO N/A
  • APVO N/A
  • EPS
  • ONCO N/A
  • APVO N/A
  • Revenue
  • ONCO $1,870,605.00
  • APVO N/A
  • Revenue This Year
  • ONCO N/A
  • APVO N/A
  • Revenue Next Year
  • ONCO N/A
  • APVO N/A
  • P/E Ratio
  • ONCO N/A
  • APVO N/A
  • Revenue Growth
  • ONCO N/A
  • APVO N/A
  • 52 Week Low
  • ONCO $0.32
  • APVO $3.65
  • 52 Week High
  • ONCO $21.40
  • APVO $399.60
  • Technical
  • Relative Strength Index (RSI)
  • ONCO 51.04
  • APVO 39.61
  • Support Level
  • ONCO $0.51
  • APVO $3.77
  • Resistance Level
  • ONCO $0.70
  • APVO $4.47
  • Average True Range (ATR)
  • ONCO 0.09
  • APVO 0.29
  • MACD
  • ONCO 0.03
  • APVO 0.08
  • Stochastic Oscillator
  • ONCO 34.45
  • APVO 38.40

About ONCO Onconetix Inc.

Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.

About APVO Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Share on Social Networks: